CD56bright NK cells exhibit potent antitumor responses following IL-15 priming

Julia Wagner(Washington University in St. Louis), Todd A. Fehniger(Washington University in St. Louis)
Journal of Clinical Investigation
October 2, 2017
10.1172/jci90387
Cited by 311

Related Papers

Fatal Leukemia in Interleukin 15 Transgenic Mice Follows Early Expansions in Natural Killer and Memory Phenotype Cd8+ T Cells
|The Journal of Experimental Medicine|2001|365
Cancer-associated fibroblast-derived Dickkopf-1 suppresses NK cell cytotoxicity in breast cancer
|Research Square|2024|1
Supplemental Methods from Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma
|Unknown|2023|0
Supplemental Methods from Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma
|Unknown|2023|0
Supplementary Methods from Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia
|Unknown|2023|0